EAST RUTHERFORD, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Cambrex
Corporation (NYSE: CBM) reported today that its Board of Directors elected
James A. Mack as President and Chief Executive Officer. Mr. Mack has been
Chairman since 1999 and in January 2006 was named Acting President and Chief
Executive Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
The Company also announced that it has retained Bear Stearns & Co, Inc. to
act as advisors to the Board of Directors in the analysis and consideration of
strategic alternatives to maximize shareholder value.
In order to provide increased financial flexibility, the Company
elected in January 2006 to use its revolving credit bank facility to prepay
$100 million of privately placed long-term debt. As a result, the Company
will record a $5.3 million charge in the first quarter 2006 for a one-time
prepayment penalty and unamortized origination fees. The prepayment does not
affect the Company's borrowing capacity.
Additionally, as part of the Company's annual analysis of the carrying
value of goodwill and long-lived assets, management has preliminarily
determined that an impairment charge of $85-100 million will be recorded in
the fourth quarter 2005. Most of the estimated impairment is within the
Biopharma segment due to lower projections of long term profitability,
partially stemming from unfavorable regulatory developments at a large client
in the fourth quarter 2005. A smaller portion of the total impairment is
related to two reporting units within the Human Health segment. Furthermore,
the Company's domestic long term profitability projections are currently being
evaluated to determine whether certain domestic tax assets are realizable for
GAAP purposes.
The Company has also determined that the Biopharma segment will not
breakeven in the fourth quarter 2005 due to the anticipated goodwill
impairment, the timing of shipments and a one-time charge related to an
investment made for a large pharma client whose potential new project has been
cancelled.
The Company expects to report fourth quarter and full year 2005 financial
results, including an update on the asset impairment and domestic tax asset
evaluation, in the February 22, 2006 earnings press release.
Forward Looking Statements
This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under
The Securities Exchange Act of 1934, including, without limitation, statements
regarding expected performance, especially expectations with respect to sales,
research and development expenditures, earnings per share, capital
expenditures, acquisitions, divestitures, collaborations, or other expansion
opportunities. These statements may be identified by the fact that words such
as "expects," "anticipates," "intends," "estimates," "believes" or similar
expressions are used in connection with any discussion of future financial and
operating performance.
The forward-looking statements contained herein are based on current plans
and expectations and involve risks and uncertainties that could cause actual
outcomes and results to differ materially from current expectations including
but not limited to, global economic trends, pharmaceutical outsourcing trends,
competitive pricing or product developments, government legislation and/or
regulations (particularly environmental issues), tax rate, interest rate,
technology, manufacturing and legal issues, changes in foreign exchange rates,
performance of minority investments, un-collectable receivables, loss on
disposition of assets, cancellation or delays in renewal of contracts, and
lack of suitable raw materials or packaging materials. For further details
and a discussion of these and other risks and uncertainties, investors are
cautioned to review the Cambrex Annual Report on Form 10-K, including the
Forward-Looking Statement section therein, and other filings with the
Securities and Exchange Commission. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to
providing products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs approximately
1,900 worldwide. For more information, please visit http://www.cambrex.com.
SOURCE Cambrex Corporation
 back to top
Related links:
http://www.cambrex.com
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Luke M. Beshar, Executive Vice President &
CFO, Phone: +1-201-804-3010, Email: luke.beshar@cambrex.com; or
Anne-Marie Hess, Sr. Director, Investor Relations,
+1-201-804-3062, annemarie.hess@cambrex.com, both of Cambrex
Corporation
|
